On keeping the trains running on time, MindMed Chief Medical Officer, Dr. Scott Freeman, commented, "Our ability to start this trial on schedule speaks volumes to both the efficiency and high caliber clinical development team MindMed has assembled to develop medicines based on psychedelics. Due to the team's experience we have an extensive playbook to draw from to manage clinical trials even under the most trying of times." MindMed Co-Founder and Co-CEO, JR Rahn, added, "We feel one of the outcomes of the COVID-19 pandemic will be increased rates of opioid addiction and mental health issues. The Mindmed team is focused on advancing 18-MC as a potential solution for the opioid crisis and other forms of addiction." About MindMed Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.